JP2005530751A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530751A5 JP2005530751A5 JP2004500908A JP2004500908A JP2005530751A5 JP 2005530751 A5 JP2005530751 A5 JP 2005530751A5 JP 2004500908 A JP2004500908 A JP 2004500908A JP 2004500908 A JP2004500908 A JP 2004500908A JP 2005530751 A5 JP2005530751 A5 JP 2005530751A5
- Authority
- JP
- Japan
- Prior art keywords
- growth hormone
- agent
- fragment
- terminal
- hormone fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000018997 Growth Hormone Human genes 0.000 claims description 13
- 108010051696 Growth Hormone Proteins 0.000 claims description 13
- 239000000122 growth hormone Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 210000004899 c-terminal region Anatomy 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 102000002265 Human Growth Hormone Human genes 0.000 claims 4
- 108010000521 Human Growth Hormone Proteins 0.000 claims 4
- 239000000854 Human Growth Hormone Substances 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000036506 anxiety Effects 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 241000283690 Bos taurus Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 230000036651 mood Effects 0.000 claims 2
- 241000282465 Canis Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 206010041247 Social fear Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- GVIYUKXRXPXMQM-BPXGDYAESA-N 221231-10-3 Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(C)C)=O)C1=CC=C(O)C=C1 GVIYUKXRXPXMQM-BPXGDYAESA-N 0.000 description 1
- 108010070305 AOD 9604 Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- -1 olive oil Chemical compound 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPS2101A AUPS210102A0 (en) | 2002-05-03 | 2002-05-03 | Method for control of depression |
| AU2003900899A AU2003900899A0 (en) | 2003-02-27 | 2003-02-27 | Method for control of depression |
| PCT/AU2003/000521 WO2003092725A1 (en) | 2002-05-03 | 2003-05-02 | Method for control of depression using c terminal growth hormone (gh) fragment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530751A JP2005530751A (ja) | 2005-10-13 |
| JP2005530751A5 true JP2005530751A5 (enExample) | 2006-06-22 |
Family
ID=29402825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500908A Pending JP2005530751A (ja) | 2002-05-03 | 2003-05-02 | 末端成長ホルモン（ｇｈ）断片を使用する鬱病の制御方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050197286A1 (enExample) |
| EP (1) | EP1501539A1 (enExample) |
| JP (1) | JP2005530751A (enExample) |
| CA (1) | CA2484396A1 (enExample) |
| WO (1) | WO2003092725A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008124072A1 (en) * | 2007-04-05 | 2008-10-16 | The Board Of Regents Of The University Of Texas System | Palmerolides: methods of preparation and derivatives thereof |
| US20110237524A1 (en) * | 2008-09-19 | 2011-09-29 | Nektar Therapeutics | Polymer conjugates of aod-like peptides |
| RU2639474C2 (ru) | 2011-12-09 | 2017-12-21 | Метаболик Фармасьютикалс Пти Лтд | Применение фрагментов гормона роста |
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| WO2014144330A1 (en) * | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of growth hormone or growth hormone receptor agonists to prevent or treat stress-sensitive psychiatric illness |
| WO2014144231A1 (en) | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| RU2020123165A (ru) * | 2018-01-15 | 2022-02-17 | Лэйтерал Ип Пти Лтд | Пептиды и их применение |
| CA3142185A1 (en) * | 2019-05-31 | 2020-12-03 | Lateral IP Pty Ltd | Peptides and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| WO1995024919A1 (en) * | 1994-03-15 | 1995-09-21 | K.U. Leuven Research & Development | New use of growth hormone |
| US20020049422A1 (en) * | 1994-03-31 | 2002-04-25 | Brewitt Barbara A. | Homeopathic preparations |
-
2003
- 2003-05-02 EP EP03718540A patent/EP1501539A1/en not_active Withdrawn
- 2003-05-02 US US10/512,959 patent/US20050197286A1/en not_active Abandoned
- 2003-05-02 JP JP2004500908A patent/JP2005530751A/ja active Pending
- 2003-05-02 WO PCT/AU2003/000521 patent/WO2003092725A1/en not_active Ceased
- 2003-05-02 CA CA002484396A patent/CA2484396A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2880084T3 (es) | Terapias que usan células adiposas y secreciones celulares | |
| JP2023071832A (ja) | フェンフルラミンを用いるドゥーゼ症候群の治療方法 | |
| JP2008519847A (ja) | 運動障害の治療方法 | |
| Lennox | Emergency and critical care procedures in sugar gliders (Petaurus breviceps), African hedgehogs (Atelerix albiventris), and prairie dogs (Cynomys spp) | |
| Brady | Research techniques for the squirrel monkey (Saimiri sp.) | |
| KR20190111105A (ko) | 프라더-윌리 증후군 및 발작 장애들을 치료하는 방법들 | |
| CN102369006A (zh) | 治疗冠状动脉和动脉的动脉瘤性蛛网膜下腔出血的方法和组合物 | |
| JP2005530751A5 (enExample) | ||
| ES2372207T3 (es) | Composiciones que comprenden alfa-cetoglutarato y su uso para modular el funcionamiento muscular. | |
| KR20090130158A (ko) | 유착 관절낭염을 치료하는 방법 | |
| ES2688577T3 (es) | Composiciones de buprenorfina en dosis altas y uso como analgésico | |
| JP2005530751A (ja) | 末端成長ホルモン（ｇｈ）断片を使用する鬱病の制御方法 | |
| Love et al. | Recovery characteristics following maintenance of anaesthesia with sevoflurane or isoflurane in dogs premedicated with acepromazine | |
| JP2017531042A (ja) | ピラゾリン由来化合物ならびに哺乳動物における変形性関節疾患に由来する炎症および疼痛に対する週間投与計画におけるその使用 | |
| GB2568928A (en) | Neuroprotective composition, preparation process thereof and medical uses thereof | |
| WO2016204230A1 (ja) | 幹細胞投与方法、競走馬または競技馬の症状改善方法、注射用容器および幹細胞注射セット | |
| Reiners et al. | How to plan and provide general anesthesia for a troop of 98 hamadryas baboons (Papio hamadryas) for contraceptive and preventative health interventions | |
| JP2023002772A (ja) | 脂肪細胞および細胞分泌物を使用する治療 | |
| Troxel | Iatrogenic traumatic brain injury during tooth extraction | |
| Guilhen et al. | A comparison of detomidine in combination with saline, morphine or methadone in horses submitted to experimental oral stimuli | |
| Akinyemi et al. | Evaluation of the perioperative analgesic effects of caudal block for herniotomy in children at the University College Hospital Ibadan, Nigeria | |
| EP3157546B1 (en) | Gcsf for use in the treatment of neurogenic immune suppression and/or prevention of related medical complications | |
| Davidson | Veterinary transdermal medications: A to Z | |
| RU2368383C1 (ru) | Продукт диетического питания "прометей", обладающий восстановительным нейрореабилитационным действием у пациентов в отдаленном периоде перенесенных острых цереброваскулярных заболеваний и травматических повреждений центральной нервной системы | |
| Chaturvedi et al. | Evaluation of glycopyrrolate-acepromazine-xylazine-thiopentone for general anaesthesia in buffalo calves |